Top-News

MEDINCELL Aktie News

Aktie
WKN:  A2N6VA ISIN:  FR0004065605 US-Symbol:  MDCLF Branche:  Biotechnologie Land:  Frankreich
27,66 €
-1,44 €
-4,95%
22:14:21 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
30,97%
KGV
-25
Index-Zuordnung
-

MEDINCELL News

09.12.25 - Businesswire
Medincell Publishes its Consolidated Half-Year Financial Results
Regulatory News:
09.12.25 - Businesswire
Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults
Regulatory News:
01.12.25 - Businesswire
Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025
Regulatory News:
27.11.25 - Businesswire
Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference
Regulatory News:
24.11.25 - Businesswire
Medincell Awarded New Grant to Fight Malaria
Regulatory News:
13.11.25 - Businesswire
Medincell Management to Participate in Fireside Chat at the Jefferies London Healthcare Conference 2025 (London - Nov. 17-20, 2025)
Regulatory News:
11.11.25 - Businesswire
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
Medincell, a clinical-​stage pharmaceutical company pioneering long-​acting injectable therapies, today announced the expanded role of Dr Grace Kim, Chief Strategy Officer, U.S. ...
11.11.25 - Businesswire
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
Regulatory News:
10.11.25 - Businesswire
Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
Regulatory News:
10.11.25 - Businesswire
Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
Medincell has been selected for inclusion in the Morgan Stanley Capital International (MSCI) World Small Cap Index, which encompasses the most liquid and high-​performing small-...
06.11.25 - Businesswire
Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)
Regulatory News:
05.11.25 - Businesswire
Medincell: UZEDY® Continues Strong Growth; Teva Setting the Stage for US NDA Submission for Olanzapine LAI in Q4 2025
Regulatory News:
22.10.25 - Businesswire
Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)
Regulatory News:
23.09.25 - Businesswire
Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
Regulatory News:
22.09.25 - Businesswire
Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
Regulatory News:
22.09.25 - Businesswire
Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®
Regulatory News:
17.09.25 - Businesswire
Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
Regulatory News:

Newssuche

Videos

newspaper
09:50 Uhr +5,70%
Technical Trading: Neues Allzeithoch im Visier
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »